Liposomal Co-Delivery of Omacetaxine Mepesuccinate and Doxorubicin for Synergistic Potentiation of Antitumor Activity (Q58759678)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

6

Yu-Kyoung Oh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

Gayong Shim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Sangbin Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Junhyeok Choi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Soondong Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Chan-Wha Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

22 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

published in

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

2178-2185

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

New and emerging combination therapies for esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Omacetaxine as an anticancer therapeutic: what is old is new again

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Nano-sized polymers and liposomes designed to deliver combination therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Enhanced tumor localization and retention of chlorin e6 in cationic nanolipoplexes potentiate the tumor ablation effects of photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Advanced materials for co-delivery of drugs and genes in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Liposomal drug delivery systems: from concept to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Paclitaxel-conjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Altering chemosensitivity by modulating translation elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Omacetaxine mepesuccinate for the treatment of leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Doxil®--the first FDA-approved nano-drug: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Enhanced transfection rates of small-interfering RNA using dioleylglutamide-based magnetic lipoplexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1317-3

Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy

21 January 2018

1 reference

12 December 2020

HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.

1 reference

12 December 2020

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

1 reference

12 December 2020

Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study,

1 reference

12 December 2020

10.1007/S11095-014-1317-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24562810%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference